Elevation Oncology, Inc. (NASDAQ:ELEV) Given Consensus Rating of “Buy” by Brokerages
Shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock […]
Shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock […]
